©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF APPLIED SCIENCES 11(1):141-147, 2026 ISSN: 2550-7931

https://doi.org/10.59298/IDOSRJAS/2026/111141147 IDOSRJAS11106

Gestational Diabetes Mellitus and Its Long-Term Health Risks: An Evidence-Based Synthesis

Nalongo Bina K.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Gestational diabetes mellitus (GDM) is a common pregnancy-related metabolic disorder with well-established short-term obstetric consequences and increasingly recognized long-term health implications for affected women. Evidence consistently demonstrates that women with a history of GDM face a substantially elevated risk of developing type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD), metabolic syndrome, and other chronic conditions later in life. This evidence-based synthesis reviews the pathophysiology of GDM, immediate obstetric outcomes, and postpartum metabolic trajectory to contextualize these long-term risks. It further examines the epidemiological evidence linking GDM to T2DM, CVD, metabolic syndrome, chronic kidney disease, and adverse outcomes in subsequent pregnancies, as well as the biological mechanisms that may underlie these associations, including persistent insulin resistance, chronic inflammation, oxidative stress, and postpartum weight gain. Current strategies for screening, prevention, and intervention, ranging from postpartum glucose testing and lifestyle modification to pharmacologic therapy when indicated, are also discussed. Despite growing knowledge, important gaps remain regarding optimal screening intervals, long-term preventive strategies, and the causal pathways linking GDM to chronic disease. Addressing these gaps through robust longitudinal research and improved postpartum follow-up may significantly reduce the long-term disease burden associated with GDM and improve women's health across the life course.

Keywords: Gestational diabetes mellitus, Type 2 diabetes mellitus, Cardiovascular disease. Metabolic syndrome and Postpartum screening.

INTRODUCTION

Gestational diabetes mellitus (GDM) is a disorder of glucose metabolism that complicates approximately 7% of pregnancies in the United States [1]. An increasing body of evidence indicates that women with a history of GDM experience an increased risk of developing type 2 diabetes mellitus (T2DM), cardiovascular disease, and other long-term health consequences [2]. The present synthesis aims to summarize the most recent findings concerning the chronic health risks associated with GDM. It begins by briefly reviewing the pathophysiology of GDM, the associated immediate obstetric risks, and the typical postpartum metabolic trajectory of affected women to contextualize the long-term health risks [3]. Individual sections detail the prevailing knowledge on each risk factor and the proposed mechanisms that link GDM to these outcomes, followed by an overview of screening, prevention, and intervention strategies. Relevant knowledge gaps and directions for future research are also identified [4].

Pathophysiology of Gestational Diabetes

Gestational diabetes mellitus (GDM) features elevated blood glucose levels first identified during pregnancy 3. GDM adversely affects maternal and fetal health, and health is closely linked to future metabolic syndrome and Type-2 diabetes [5]. Pregnancies are initially characterized by increased insulin levels, insulin resistance, and increased post-prandial glucose, fats, and amino acids [6]. Maternal weight gain is documented to affect

pregnancy outcomes with obesity, sexually dimorphic fetal (size) outcomes, and thus metabolic derangement and GDM screening are recommended. Following pregnancy, postpartum blood glucose is also key to predicting future health outcomes. Detection of Type-2 diabetes is in some jurisdictions performed as early as 6 weeks postpartum [7].

Immediate Obstetric Outcomes Associated with Gestational Diabetes

Gestational diabetes mellitus (GDM) is a specific type of diabetes diagnosed during pregnancy and is a growing health concern worldwide [4]. In 2019, 880,000 cases of GDM were newly reported; approximately 80% of these cases were in low- and middle-income countries; and women with GDM had a two-to-threefold increased risk of developing type 2 diabetes mellitus (T2DM) 5 to 10 years postpartum [5]. In addition to the increased risk of T2DM, GDM is reported to significantly raise the risk of long-term health problems, including cardiovascular disease (CVD), hypertension, and metabolic syndrome among women. Considering that pregnancy is a unique opportunity for health education and lifestyle modification that can have long-term health benefits both for the woman and the child, it is imperative to increase awareness and understanding of GDM [6]. All types of diabetes mellitus in pregnancy are associated with increased risks of maternal, fetal, and neonatal adverse outcomes. Poorly controlled GDM can lead to complications similar to those of pre-gestational diabetes. Maternal short-term complications of diabetes include preeclampsia, infection, and cesarean delivery [9]. The risk of fetal and neonatal complications is higher in pre-gestational diabetes, but uncontrolled GDM is associated with a significant risk [5]. The frequency of fetal and neonatal complications varies depending on the type and control level of maternal diabetes, presence of vascular or obstetrical complications, and population studied [3]. Fetal complications of all types of diabetes include stillbirth, which occurs more frequently in poorly controlled pre-gestational and GDM; congenital malformations; macrosomia; and intrauterine growth restriction. Perinatal and neonatal complications include birth trauma, respiratory distress syndrome, and neonatal death, independent of maternal diabetes type. Macrosomia is generally defined as a birth weight of 4,000 grams or more, with some guidelines recommending a threshold of 4,500 grams [4].

Postpartum Metabolic Trajectory

After giving birth, the postpartum period is critically important for the health and well-being of both the mother and the baby [6]. In women with a history of gestational diabetes mellitus (GDM), the time after delivery is also a particularly vulnerable period for the development of glucose intolerance, leading to the consensus to routinely screen for diabetes in the early postpartum period [5]. The risk remains elevated even if their blood glucose levels return to normal and does not reduce with time [5]. Longitudinal studies have demonstrated that the majority of women previously diagnosed with GDM (50% to 80% within 5–10 years) or with glucose intolerance during pregnancy develop type 2 diabetes mellitus (T2DM) in the future [6]. The current prevalence of T2DM among women with a history of GDM is approximately 5–15%, with an incidence as high as 61% in certain regions [10]. Thus, the trajectory toward obesity and cardiovascular disease starts earlier in women with a prior history of GDM, particularly in the first 10–15 years after a GDM pregnancy [15]. The manifestation of increased adiposity may commence even postpartum and prohibit the attainment of optimal body weight and metabolic control in many women [11].

Long-term Health Risks for Women with a History of Gestational Diabetes

The long-term health risks of developing T2DM and CD after GDM have been investigated in multiple studies. A recent retrospective cohort study in Hong Kong showed increased health risks, particularly for diabetic patients, among women with a history of GDM, as well as persistent elevation of these risks beyond twenty years postpartum [7]. Although the most significant contributions to cardiovascular disease (CVD), chronic kidney disease (CKD), and all-cause mortality stem from the development of New-onset Diabetes after GDM (NODAG), women without diabetes still present a higher hazard ratio than women with no GDM [11]. A systematic review of female patients reported an association between GDM and the subsequent incidence of CKD, recurrent GDM, and increased perinatal and maternal complications in subsequent pregnancies [8]. For CKD in particular, past GDM bears a significant association among Black women [13]. Regarding breast cancer, a potential link has been suggested, but the inability of the studies analysed to exclude confounding risk factors properly remains problematic. Overall, the available results do not allow firm conclusions to be drawn about long-term associations between GDM and a number of chronic pathologies in women [16]. Studies examining the long-term association of GDM with T2DM have provided more solid evidence [9]. Multiple prospective cohorts indicate that a prior history of GDM reliably predicts an early increase in the incidence of T2DM, with a review of epidemiological literature suggesting that as many as 60% of women will go on to develop the disease within fifteen years of their diagnosis [16]. The increased risk remains long after the resolution of GDM and appears to persist, if at a lower level, among women who fail to experience the condition in subsequent pregnancies [16]. The role of GDM in diabetes development is frequently thought to be mediated by a change in insulin resistance, with these variations

leading to independent trajectories of post-partum weight gain, and the examination of the combined effects of obesity and prior GDM on the subsequent development of T2DM putatively reinforces this hypothesis [15]. The deterioration of pre-existing metabolic aberrations and the emergence of additional pathologies indicative of metabolic syndrome following GDM have also been proposed [15].

Type 2 Diabetes Mellitus

Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy (International Association of Diabetes in Pregnancy Study Groups, 2010). GDM typically emerges during the second or third trimester and usually resolves soon after delivery [14]. However, according to the most recent meta-analysis, around 37% of women with a history of GDM develop type 2 diabetes (T2D) within 5–10 years of delivery [1]. The risk increases to 68% over a lifetime. GDM is associated with a higher risk of T2D even in the short term: cumulative incidence is around 12% at 5 years and 26% at 10 years postpartum. These cumulative incidences are around three times higher in women with GDM than in those with normoglycaemia during pregnancy [12]. Obesity, an essential risk factor for T2D, contributes to the high prevalence of postpartum glucose intolerance (PGI) among GDM patients. Gestational diabetes mellitus is associated with a higher risk of PGI when patients are of normal weight [12]. Interestingly, preventive strategies targeting obesity-maintaining postpartum interventions in women with GDM (e.g., lifestyle modification and metformin treatment) prevent T2D. Preventive strategies targeting obesity, such as weight-loss interventions, were found to lower the risk of developing T2D [13].

Gestational Diabetes and Risk of Cardiovascular Disease

Compared with unaffected women of childbearing age, those with a history of gestational diabetes have an increased risk of cardiovascular disease and risk factors [17]. State-of-the-art review articles note the association of gestational diabetes and subsequent cardiovascular disease within the broader context of maternal chronic metabolic disorders [18]. Cardiovascular outcomes generally studied include coronary heart disease, nonfatal myocardial infarction, heart failure, cerebral stroke, and overall cardiovascular disease [15]. Several studies have explored the association between the incidence of cardiovascular disease and the history of gestational diabetes. The results are inconsistent: a meta-analysis of six population-based cohort studies of 115,379 women indicated that gestational diabetes did not predict future coronary heart disease and that the association was fully mediated by the intermediate variable of type 2 diabetes [10]. However, gestational diabetes was significantly and independently associated with other cardiovascular disorders (other than coronary heart disease) and with a mosaic of factors associated with cardiovascular risk [11]. Further cohort studies conducted in Changzhou, China, and in the United States reported that the history of gestational diabetes was a risk factor that raised the likelihood of cardiovascular disease, either directly or indirectly, and independently of type 2 diabetes. Remaining questions persist on the direct association of the history of gestational diabetes and incident cardiovascular disease, in particular on whether the relationship holds once adjustments are made for potential confounders such as obesity [19]. Gaps in the investigation include a trend to treat the history of gestational diabetes as a singleton descriptor, in contradistinction to addressing details of the preceding cases, and a deficit of longitudinal studies monitoring the evolution over time of gestational diabetes [18].

Metabolic Syndrome

Women with a history of gestational diabetes (GDM) exhibit an increased risk of developing metabolic syndrome, a condition characterized by a constellation of distinct components that elevate a person's risk for type 2 diabetes and cardiovascular disease [11]. An adult is diagnosed with metabolic syndrome if they display at least three of the following five components: abdominal obesity, elevated serum triglycerides, reduced high-density lipoprotein (HDL) cholesterol, elevated blood pressure, and increased fasting plasma glucose [12]. The clinical diagnosis of metabolic syndrome during pregnancy was introduced in a Women's Health Initiative Obesity Working Group publication in 2012. Components of metabolic syndrome also measured in earlier gestation are associated with adverse pregnancy and fetal outcomes [13].

Subsequent Pregnancies and Perinatal Outcomes

Women with a history of gestational diabetes (GDM) face increased risk for adverse perinatal outcomes if they become pregnant again [3]. Adequate glucose control is crucial for achieving favorable clinical outcomes, but many women do not engage in preventive behavior before conception or receive adequate treatment once pregnancy is confirmed [14]. For some women, the risk of developing type 2 diabetes (T2D) cannot be managed adequately in the postpartum period, resulting in a higher likelihood of osteoporosis and associated fractures, cardiovascular disease, metabolic syndrome, and chronic kidney disease during subsequent pregnancies [4]. Although women with a history of GDM need to be specifically addressed, such pregnancies can also be complicated by pre-existing diabetes. Maternal diabetes, whether pre-existing or gestational, is associated with numerous adverse obstetric and neonatal outcomes. All types of maternal diabetes carry an elevated risk of fetal

congenital anomalies, particularly involving the heart, kidney, and urinary tract [7]. These vascular-related anomalies appear to be linked to the duration of maternal hyperglycemia during the first trimester. Inadequate glycemic control increases the risk of preterm birth and obstetric complications such as preeclampsia. An elevated risk of stillbirth accompanies pre-existing diabetes, although such cases remain rare in the United States, especially among women with GDM [5].

Mechanisms Linking Gestational Diabetes to Future Risk

Gestational diabetes mellitus (GDM) is a strong, independent risk factor for future type 2 diabetes (T2DM), cardiovascular disease (CVD), and metabolic syndrome among women [2]. The mechanisms linking GDM to a higher future risk of chronic disease and related maternal obesity remain unclear, partly due to difficulties associated with human studies [13]. Longitudinal studies of rodent models demonstrate that GDM induces metabolic dysregulation in mothers and offspring similar to obesity-induced metabolic syndrome. Maternal insulin resistance (IR) before GDM onset is a predisposing factor [3]. The metabolic disturbances observed consist of enhanced placental leptin and ectopic lipid accumulation, which occur in parallel with increased oxidative stress and altered levels of inflammatory mediators. These disturbances drive inflammation, altering gene expression that increases maternal and neonatal susceptibility to GDM, metabolic syndrome, and obesity, and perinatal complications such as macrosomia and malformations. Evidence from clinical studies implicates helping to continue oxidative stress and chronic low-grade inflammation in the accelerated pathogenesis of GDM-related disorders [1, 4].

Screening, Prevention, and Intervention Strategies

Women with a history of GDM have a substantial lifetime risk of developing type 2 DM, cardiovascular disease, and other components of MSS by midlife, leading to recommendations for postpartum screening and lifestyle interventions [15]. Screening strategies are guided by preconception and/or early pregnancy risk factor assessment; however, universal screening is endorsed by several organizations because it improves identification of women at risk of perinatal complications and subsequent type 2 DM [16]. Nevertheless, the optimal interval, modalities, and strategies for repeat screening in the early postpartum period remain debated, with few large studies evaluating methods to increase screening adherence [2]. Evidence suggests that glucose intolerance frequently persists after GDM and that, although the risk of subsequent type 2 DM is highest within 5 years of GDM, many women remain undiagnosed at this time[3]. Weight loss and/or exercise at any time reduces the incidence of type 2 DM; thus, postpartum counseling focusing on glucose status and lifestyle intervention should be reinforced beyond this window [11].

Postpartum Screening and Recall Strategies

Women with a history of gestational diabetes mellitus (GDM) have an approximate 50% risk of developing type 2 diabetes mellitus (T2DM) within 5 to 10 years, despite having normal glucose tolerance at 6 to 12 weeks postpartum [17]. Moreover, a considerable number develop cardiovascular disease, metabolic syndrome, or related disorders, with increasingly evident multimorbidity in diabetes [18]. Structured postpartum follow-up improves long-term outcomes yet is underutilized. Systematic reminders, particularly during preconception care or early pregnancy, may increase attendance [13]. The limited number of women at risk who comply with 75-g OGTTs after GDM suggests that subsequent perinatal outcomes and metabolic trends should be further integrated alongside T2DM in GDM evaluations [12].

Lifestyle Interventions

Women with a history of gestational diabetes mellitus (GDM) are at high risk for type 2 diabetes mellitus (T2DM) postpartum, with an estimated 20-50% of women progressing to overt glucose intolerance or diabetes within 5-10 years after the index pregnancy [19]. Rigorous, evidence-based lifestyle intervention programs aiming to modify diet, physical activity, and behavior have demonstrated substantial reductions in the incidence of T2DM in women with a history of GDM [20]. Overall, GDM-specific lifestyle interventions appear to confer clinically meaningful reductions in risk for GDM-affected women, though the magnitude of benefit is smaller than that observed with GDM-straddling lifestyle interventions in older populations receiving intensive, 1-on-1 treatment [20]. Modifications of lifestyle behaviors can improve outcomes in women with a history of GDM, especially by ameliorating surges in cardiovascular risk factors following pregnancy and reducing the risk of subsequent GDM in the next pregnancy [11]. Nevertheless, notable implementation challenges persist [11]. Existing interventions emphasize either postpartum screening and recall strategies or diet and exercise adjustments, with little attention directed toward breastfeeding incentives [14].

Pharmacologic Approaches when Indicated

Untreated GDM has been associated with substantial maternal and fetal perinatal morbidities [21], and current recommendations endorse pharmacologic therapy when lifestyle modifications alone do not achieve specified glycemic targets within 1–2 weeks. The pharmacological agents mentioned most frequently in the GDM literature

are insulin, glyburide, and metformin [22]. Insulin remains the standard first-line agent because it is effective, specific, and does not cross the placenta [21]. The decision to initiate pharmacologic therapy is made on an individual basis, but clinical trials have suggested glycemic targets may be relaxed for some patients without compromising safety. Targets of fasting glucose ≤95 mg/dL and 1-h postprandial levels ≤140 mg/dL are still safe [20]. The available evidence suggests pharmacologic agents other than insulin may be preferred on a patient-by-patient basis, owing to convenience and less invasive administration, but additional clinical studies are needed to strengthen the information base for GDM populations [13].

Gaps in Knowledge and Areas for Future Research

Gaps in many areas of research deal with not only metabolic consequences but also several other aspects of the subject of gestational diabetes mellitus [18]. Given the frequency of GDM, there is an ongoing need for better evidence on possible long-term health outcomes, especially studies based on comprehensive records of GDM diagnosis and associated long-term health results [19]. There also exists considerable uncertainty about the extent to which human health, and in particular the development of excessive weight gain and obesity, can be affected through in utero programming associated with maternal GDM and how such consequences can be avoided [23]. In many cases, studies have included a sufficient degree of rigor, such as a prospective design, a multi-ethnic population, a large sample size, and a gold standard assessment of the outcome, that the limitations, including low study quality, residual confounding, reverse causation bias, inadequate follow-up, and underpowered analyses, preclude drawing firm conclusions [21]. Moreover, most studies have been post hoc and have assessed prognostic variables contemporaneous with the outcome of interest, preventing causal inference. The large number of risk factors currently associated with the metabolic consequences of GDM is in itself suggestive of a need for further research aimed at simplifying decision-making [23-37].

CONCLUSION

Gestational diabetes mellitus is not merely a transient complication of pregnancy but a critical marker of future metabolic and cardiovascular vulnerability. Women with a history of GDM are at markedly increased risk of developing type 2 diabetes mellitus, cardiovascular disease, metabolic syndrome, and related chronic conditions, with these risks persisting for decades after the index pregnancy. The evidence indicates that this heightened risk is driven by persistent insulin resistance, postpartum metabolic dysregulation, weight gain, and chronic low-grade inflammation, often compounded by underlying obesity and socioeconomic factors. Pregnancy and the postpartum period represent unique opportunities for early identification of high-risk women and the implementation of preventive strategies. Regular postpartum screening, sustained lifestyle interventions, and, when necessary, pharmacologic treatment have demonstrated potential to reduce progression to overt disease, yet adherence to follow-up and long-term care remains suboptimal. Future research should prioritize longitudinal, well-designed studies to clarify causal mechanisms, refine risk stratification, and determine the most effective, scalable interventions. Strengthening health systems to support long-term monitoring and prevention after GDM could substantially improve maternal health outcomes and reduce the intergenerational burden of metabolic disease.

REFERENCES

1. Rayanagoudar G, Hashi AA, Zamora J, Khan KS, Hitman GA, Thangaratinam S. Quantification of the type 2 diabetes risk in women with gestational diabetes: a systematic review and meta-analysis of 95,750 women. Diabetologia. 2016 Jul;59(7):1403-11.
2. Brody SC, Harris R, Lohr K. Screening for gestational diabetes: a summary of the evidence for the US Preventive Services Task Force. Obstetrics & Gynecology. 2003 Feb 1;101(2):380-92.
3. Ugwu OP, Ogenyi FC, Ugwu CN, Basajja M, Okon MB. Mitochondrial stress bridge: Could muscle-derived extracellular vesicles be the missing link between sarcopenia, insulin resistance, and chemotherapy-induced cardiotoxicity?. Biomedicine & Pharmacotherapy. 2025 Dec 1;193:118814.
4. Plows JF, Stanley JL, Baker PN, Reynolds CM, Vickers MH. The pathophysiology of gestational diabetes mellitus. International journal of molecular sciences. 2018 Oct 26;19(11):3342.
5. Daniela R. Fetal and neonatal complications of diabetic pregnancy. The Moldovan Medical Journal. 2017;60(4):50-6.
6. Ugwu OP, Ogenyi FC, Ugwu CN, Basajja M, Okon MB. Mitochondrial stress bridge: Could muscle-derived extracellular vesicles be the missing link between sarcopenia, insulin resistance, and chemotherapy-induced cardiotoxicity?. Biomedicine & Pharmacotherapy. 2025 Dec 1;193:118814.
7. Moon JH, Kwak SH, Jang HC. Prevention of type 2 diabetes mellitus in women with previous gestational diabetes mellitus. The Korean journal of internal medicine. 2017 Jan 1;32(1):26.
8. Paul-Chima UO, Nneoma UC, Bulhan S. Metabolic immunobridge: Could adipose-derived extracellular vesicles be the missing link between obesity, autoimmunity, and drug-induced hepatotoxicity?. Medical Hypotheses. 2025 Sep 28:111776.

9. Jacobsen KH, Aalders J, Sølling K, Andersen MS, Snogdal LS, Christensen MH, Vinter CA, Højlund K, Jensen DM. Long-term metabolic outcomes after gestational diabetes mellitus (GDM): results from the Odense GDM follow-up study (OGFUS). Journal of Diabetes Research. 2022;2022(1):4900209.
10. Paul-Chima UO, Nneoma UC, Bulhan S. Metabolic immunobridge: Could adipose-derived extracellular vesicles be the missing link between obesity, autoimmunity, and drug-induced hepatotoxicity?. Medical Hypotheses. 2025 Sep 28:111776.
11. Zhang X, Wu H, Lau ES, Fan B, Tsoi KY, Tam CH, Yang A, Shi M, Chow E, Kong AP, Chan JC. Health impacts of new-onset diabetes in women post-gestational diabetes mellitus: Insights from Hong Kong's territory-wide data. Journal of Diabetes Investigation. 2024 Jun;15(6):772-81.
12. Ugwu OP, Ogenyi FC, Ugwu CN, Ugwu MN. Gut microbiota-derived metabolites as early biomarkers for childhood obesity: A policy commentary from urban African populations. Obesity Medicine. 2025 Sep 1;57:100641.
13. Ugwu OP, Ogenyi FC, Ugwu CN, Ugwu MN. Gut microbiota-derived metabolites as early biomarkers for childhood obesity: A policy commentary from urban African populations. Obesity Medicine. 2025 Sep 1;57:100641.
14. Flachs Madsen LR, Gerdøe-Kristensen S, Lauenborg J, Damm P, Kesmodel US, Lynge E. Long-term follow-up on morbidity among women with a history of gestational diabetes mellitus: a systematic review. The Journal of Clinical Endocrinology & Metabolism. 2022 Sep 1;107(9):2411-23.
15. Bao W, Yeung E, Tobias DK, Hu FB, Vaag AA, Chavarro JE, Mills JL, Grunnet LG, Bowers K, Ley SH, Kiely M. Long-term risk of type 2 diabetes mellitus in relation to BMI and weight change among women with a history of gestational diabetes mellitus: a prospective cohort study. Diabetologia. 2015 Jun;58(6):1212-9.
16. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Sustainable development goals (SDGs) and resilient healthcare systems: Addressing medicine and public health challenges in conflict zones. Medicine. 2025 Feb 14;104(7):e41535.
17. Ugwu OP, Okon MB, Alum EU, Ugwu CN, Anyanwu EG, Mariam B, Ogenyi FC, Eze VH, Anyanwu CN, Ezeonwumelu JO, Egba SI. Unveiling the therapeutic potential of the gut microbiota–brain axis: Novel insights and clinical applications in neurological disorders. Medicine. 2025 Jul 25;104(30):e43542.
18. Archambault C, Arel R, Filion KB. Gestational diabetes and risk of cardiovascular disease: a scoping review. Open Medicine. 2014 Jan 7;8(1):e1.
19. Ellerbrock J, Hubers E, Ghossein-Doha C, Schiffer V, Alers RJ, Jorissen L, Neer JV, Zelis M, Janssen E, Landewé-Cleuren S, Haarlem AV. Second-Trimester constituents of the metabolic syndrome and pregnancy outcome: an observational cohort study. Nutrients. 2022 Jul 18;14(14):2933.
20. Grieger JA, Bianco-Miotto T, Grzeskowiak LE, Leemaqz SY, Poston L, McCowan LM, Kenny LC, Myers JE, Walker JJ, Dekker GA, Roberts CT. Metabolic syndrome in pregnancy and risk for adverse pregnancy outcomes: A prospective cohort of nulliparous women. PLoS Medicine. 2018 Dec 4;15(12):e1002710.
21. Edyedu I, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI. The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. Medicine. 2025 Feb 14;104(7):e41381.
22. Ugwu CN, Ugwu OP, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI, Uti DE. Sustainable development goals (SDGs) and resilient healthcare systems: Addressing medicine and public health challenges in conflict zones. Medicine. 2025 Feb 14;104(7):e41535.
23. Habibi N, Mousa A, Tay CT, Khomami MB, Patten RK, Andraweera PH, Wassie M, Vandersluys J, Aflatounian A, Bianco-Miotto T, Zhou SJ. Maternal metabolic factors and the association with gestational diabetes: a systematic review and meta-analysis. Diabetes/metabolism research and reviews. 2022 Jul;38(5):e3532.
24. Akinyemi OA, Weldeslase TA, Odusanya E, Akueme NT, Omokhodion OV, Fasokun ME, Makanjuola D, Fakorede M, Ogundipe T, Makanjuola DI. Profiles and outcomes of women with gestational diabetes mellitus in the United States. Cureus. 2023 Jul 4;15(7).
25. Raets L, Beunen K, Benhalima K. Screening for gestational diabetes mellitus in early pregnancy: what is the evidence?. Journal of Clinical Medicine. 2021 Mar 18;10(6):1257.
26. Cosson E, Benbara A, Pharisien I, Nguyen MT, Revaux A, Lormeau B, Sandre-Banon D, Assad N, Pillegand C, Valensi P, Carbillon L. Diagnostic and prognostic performances over 9 years of a selective

screening strategy for gestational diabetes mellitus in a cohort of 18,775 subjects. Diabetes care. 2013 Mar 1;36(3):598-603.

27. Ongesa TN, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Okon MB, Ejemot-Nwadiaro RI. Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response. Medicine. 2025 Jan 17;104(3):e41279.
28. Edyedu I, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Ejemot-Nwadiaro RI, Okon MB, Egba SI. The role of pharmacological interventions in managing urological complications during pregnancy and childbirth: A review. Medicine. 2025 Feb 14;104(7):e41381.
29. Benhalima K, Verstraete S, Muylle F, Decochez K, Devlieger R, Crombrugge PV, Verhaegen A, Wens J, Mathieu C. Implementing a reminder system in the northern part of Belgium to stimulate postpartum screening for glucose intolerance in women with gestational diabetes: the "sweet pregnancy" project. International journal of endocrinology. 2017;2017(1):3971914.
30. Korpi-Hyövälti E, Laaksonen DE, Schwab U, Heinonen S, Niskanen L. How can we increase postpartum glucose screening in women at high risk for gestational diabetes mellitus?. International journal of endocrinology. 2012;2012(1):519267.
31. Goveia P, Cañon-Montañez W, Santos DD, Lopes GW, Ma RC, Duncan BB, Ziegelman PK, Schmidt MI. Lifestyle intervention for the prevention of diabetes in women with previous gestational diabetes mellitus: a systematic review and meta-analysis. Frontiers in endocrinology. 2018 Oct 5;9:583.
32. Ongesa TN, Ugwu OP, Ugwu CN, Alum EU, Eze VH, Basajja M, Ugwu JN, Ogenyi FC, Okon MB, Ejemot-Nwadiaro RI. Optimizing emergency response systems in urban health crises: A project management approach to public health preparedness and response. Medicine. 2025 Jan 17;104(3):e41279.
33. O'Reilly SL, Dunbar JA, Versace V, Janus E, Best JD, Carter R, Oats JJ, Skinner T, Ackland M, Phillips PA, Ebeling PR. Mothers after Gestational Diabetes in Australia (MAGDA): a randomised controlled trial of a postnatal diabetes prevention program. PLoS Medicine. 2016 Jul 26;13(7):e1002092.
34. Kelley KW, Carroll DG, Meyer A. A review of current treatment strategies for gestational diabetes mellitus. Drugs in context. 2015 Jul 15;4:212282.
35. Okon MB, Ugwu OP, Ugwu CN, Ogenyi FC, Swase DT, Anyanwu CN, Eze VH, Ugwu JN, Akinola SA, Mujinya R, Anyanwu EG. From pandemics to preparedness: harnessing AI, CRISPR, and synthetic biology to counter biosecurity threats. Frontiers in Public Health. 2025 Nov 26;13:1711344.
36. Carroll DG, Kelley KW. Review of metformin and glyburide in the management of gestational diabetes. Pharmacy practice. 2014 Mar 15;12(4):528.
37. Semnani-Azad Z, Gaillard R, Hughes AE, Boyle KE, Tobias DK, Perng W. Precision stratification of prognostic risk factors associated with outcomes in gestational diabetes mellitus: a systematic review. Communications medicine. 2024 Jan 12;4(1):9.

CITE AS: Wambui Kibibi J. (2026). Gestational Diabetes Mellitus and Its Long-Term Health Risks: An Evidence-Based Synthesis. IDOSR JOURNAL OF APPLIED SCIENCES 11(1):141-147.
https://doi.org/10.59298/IDOSRJAS/2026/111141147